Medicine@Yale

This is the third CTSA renewal for Yale, which was the only site in New England to receive funding when the program began in 2006.

Before COVID-19, some Yale researchers had worked for years in other vaccine development efforts focused on conquering some the world’s most malicious and deadly diseases. Those efforts continue on trajectories that may be reshaped by knowledge gained from the COVID-19 experience.

To have the juxtaposition of being at an institution with such a rich history, but one that can, and wants to, move forward is very special, she says.

Made the cancer hospital that bears his name possible with a generous gift in 2007

Indra Nooyi was so impressed by Albert Ko’s extensive knowledge and scientific approach that she and her husband, Raj Nooyi, a global supply chain executive, contributed a $3 million gift to establish the Raj and Indra Nooyi Professor of Public Health at Yale.

In a clinical trial led by Kevan Herold, MD, teplizumab prevented or delayed clinical diagnosis.

Oleic acid, a fatty acid found in many foods, may counteract the autoimmune effect of multiple sclerosis.

Ruslan Medzhitov, PhD, is looking to conceptual models—such as systems theory, control theory, adaptation, and trade-offs—from fields like physics, economics, math, and evolutionary biology and applying them to broad questions about human health.

The center will have an ambitious goal: to produce better diagnoses, treatments, and ultimately cures for these diseases. It will also work toward vaccine development.

Seventeen years after it began, in 2005, publication of Medicine@Yale is coming to an end with this issue.